A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer

• Published in: Gynecologic oncology 2011-04, Vol.121 (1), p.112-117
• Main Authors: Geller, Melissa A, Ivy, Joseph J, Ghebre, Rahel, Downs, Levi S, Judson, Patricia L, Carson, Linda F, Jonson, Amy L, Dusenbery, Kathryn, Vogel, Rachel Isaksson, Boente, Matthew P, Argenta, Peter A
• Format: Article
• Language: English
• Subjects: Adult; Advanced stage; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Brachytherapy - adverse effects; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carcinoma, Endometrioid - drug therapy; Carcinoma, Endometrioid - pathology; Carcinoma, Endometrioid - radiotherapy; Chemotherapy; Combined Modality Therapy - adverse effects; Disease-Free Survival; Dose Fractionation; Endometrial cancer; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - pathology; Endometrial Neoplasms - radiotherapy; Female; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Humans; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - radiotherapy; Neoplasm Staging; Obstetrics and Gynecology; Radiation; Taxoids - administration & dosage; Taxoids - adverse effects; Young Adult
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2010.12.338

Abstract Objective To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Methods Patients with surgically staged III–IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m2 ) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy) ± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan–Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21–81 years). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent = 1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7–70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82–99%), at 3 years 90% (75–96%), and at 5 years 71% (45–86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72–94%), at 3 years 71% (51–83%), and at 5 years 64% (42–80%). Conclusions “Sandwiching” radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.